格拉米西丁A在骨髓性白血病中的抗癌作用
Syeda Maham1, Mudassir Khan1, Aleeha Noor1
1Department of Biomedicine, Atta ur Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
Discover oncology
|October 9, 2025
概括
格拉米西丁A (GA) 通过向Wnt/β-catenin通路中的关键基因,有效地抑制白血病细胞生长. 这种抗生素显示了作为急性原核细胞白血病 (APL) 和慢性髓性白血病 (CML) 的安全治疗候选人的承诺,而不会造成红细胞损伤.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 白血病,包括急性髓性白血病 (AML),急性原肌细胞性白血病 (APL) 和慢性髓性白血病 (CML),仍然是一个重要的健康挑战,治疗选择有限.
- 尽管FDA批准的治疗方法取得了进展,但APL和CML的复发和缺乏确定的治疗方法仍然存在.
- 抗生素格拉米西丁A (GA) 作为抗癌剂的潜力已得到认可,但其在白血病中的特定机制在很大程度上尚未被探索.
研究的目的:
- 为了研究抗癌潜力,并阐明格拉米西丁A (GA) 在APL和CML细胞系中的作用机制.
- 评估GA对参与白血病发生的扩散和关键分子通路的影响.
- 评估GA在红细胞完整性方面的安全性.
主要方法:
- 用药理和生化分析来评估GA的抗癌作用.
- 进行基因表达分析以确定GA的分子标,重点关注Wnt/β-catenin通路的调节者.
- 结合性研究与标准疗法 (Imatinib治疗CML,ATRA治疗APL) 进行,以评估附加效应.
主要成果:
- 格拉米西丁A显著抑制了APL和CML细胞系的增殖潜力,独立于亡诱导 (p < 0.05和p < 0.0001).
- GA降低了AXL-RTK和EYA3基因的表达,这些基因是Wnt/β-catenin通路的关键调节者.
- 观察到Wnt/β-catenin向基因的下调,包括c-Myc和Axin2,当GA与伊马替尼或ATRA结合时,与增强的抗癌作用相关 (p < 0.0001).
- 重要的是,GA在任何测试的抑制度下都没有诱导红细胞的血液溶解.
结论:
- 格拉米西丁A在降低APL和CML的白血病产生能力方面显示出显著的潜力.
- 亚甘氨酸表现出有利的安全性概况,红细胞血解的缺失证明了这一点.
- 这些发现表明,格拉米西丁A可能是一个可行的治疗候选人或替代品来管理APL和CML.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Differentiation of Common Myeloid Progenitor Cells
3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K


